Law360, New York (June 03, 2009) -- A top Federal Trade Commission official on Wednesday urged lawmakers to pass legislation banning so-called reverse payment patent settlements between brand-name pharmaceutical companies and their generic competitors.
The FTC's Bureau of Competition Director Richard A. Feinstein told a House Judiciary Committee hearing that the settlements now common in U.S. drug industry patent disputes are anti-competitive, and block...
